stem-cell-research-2017_posters-accepted-abstracts

18 / 18

Page 97
conferenceseries.com
Volume 8, Issue 1 (Suppl) J Cell Sci Ther
ISSN: 2157-7013 JCEST, an open access journal Stem Cell Research 2017
March 20-22, 2017
March 20-22, 2017 Orlando, USA
8th World Congress and Expo on
Cell & Stem Cell Research
Role of point of care pharmacist in patient receiving oral chemotherapeutic agents
Naureen Wajid
American Hospital Dubai, UAE
Background: Oral chemotherapeutic agents have been conceptualized as a convenient, less toxic form of therapy that is preferred
by the patients. However many safety issues related to chemotherapeutic agents are appreciated. Safety issues which include lack of
check and balance to avoid medication errors, drug interactions, side effects, administration issues, lack of patient adherence and
shift of responsibility for managing a potential complicated oral regimen fromOncologists, nurses and Pharmacists to the patient and
caregivers. As a result of these factors Oncology Pharmacist can be utilized as Point of Care Pharmacist (PCP) and can be consulted
to identify drug related problems (DRPs) and to provide patient counseling.
Objectives: To evaluate the 1) role of Point of Care Pharmacist (PCP) service provided to the patients receivingOral Chemotherapeutic
Agents 2) Number of DRPs identified by the PCP and 3) Type of recommendations made for management of DRPs.
Study Design: This is prospective observational study. PCP can help the patient with everything to get the Oral Chemotherapy to
start and provides the cost estimate for insurance, corporate and self payers. PCP can help in designing standard order forms for Oral
Chemotherapeutic agents which includes all the information including diagnosis, cycle number, and body surface area and dosing
calculations. PCP met with patient receiving oral chemotherapeutic agents and takes the Patient medication history (PMH), check
for drug-drug, drug-food interactions, and provides patient counseling and patient education materials. Complete pre and post
counseling questionnaire to capture the understanding of their oral chemotherapeutic agents.
Methodology: PCP RECEIVES PROTOCOL → PROVIDE COST ESTIMATE → MEDICATION PROCUREMENT → PCP
RECEIVES CONSULT → PRE –COUNSELLING QUESTIONNAIRE → PCP COMPLETES PMH , INTERACTION CHECKING
,COUNSELLING & PROVIDING PATIENT EDUCATION MATERIALS →POST COUNSELLING QUESTIONNAIRE →
RECOMMENDATIONS
Intended outcomes: The intended outcomes are as follows: Peace of mind for physicians, nurses and patients by expert support from
point of care pharmacist, standard order forms for oral chemotherapy in order to keep the cycle track, reducing medication errors
by multiple checking of order forms from oncologists, PCP and nurses, helps in resolving tough administration issues e.g. IV to oral
switching, can be crushed or not, can be given through nasogastric tubes, extemporaneous compounding options etc., identifies drug
interactions, communicate to oncologists and document the recommendations, reduction in DRPs and to improve understanding of
oral chemotherapy by the patients.
Conclusion: The study will suggest that the consult service of PCP for oral chemotherapeutic agent is beneficial and should be
continued.
J Cell Sci Ther 2017, 8:1 (Suppl)